FDA Advisory Committee Recommends AstraZeneca's TRUQAP for PTEN-Deficient Prostate Cancer

Key Takeaways

• FDA Advisory Committee voted 7-1 in favor of TRUQAP (capivasertib) for PTEN-deficient metastatic hormone-sensitive prostate cancer
• The recommendation is based on positive results from the CAPItello-281 Phase III trial showing favorable benefit-risk profile
• FDA decision expected by August 2025, potentially bringing first AKT inhibitor to prostate cancer treatment

---

The US Food and Drug Administration’s Oncologic Drugs Advisory Committee (ODAC) has delivered a strong endorsement for AstraZeneca’s TRUQAP® (capivasertib), voting 7-1 with one abstention to recommend approval for treating patients with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC).

Breakthrough in Precision Prostate Cancer Treatment

The committee’s recommendation centers on TRUQAP’s use in combination with abiraterone and androgen deprivation therapy (ADT), representing a precision medicine approach targeting a specific genetic subset of prostate cancer patients. The favorable vote was based on data from the CAPItello-281 Phase III trial, which demonstrated a compelling benefit-risk profile for this patient population.

Capivasertib works as an AKT inhibitor, targeting a crucial cellular pathway often dysregulated in PTEN-deficient tumors. PTEN loss occurs in approximately 20-30% of metastatic prostate cancers and is associated with more aggressive disease and resistance to standard hormone therapies.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for oncology - prostate cancer, with TRUQAP, capivasertib, and abiraterone most exposed to upcoming decisions. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Clinical Trial Results Drive Strong Committee Support

The CAPItello-281 trial evaluated the triple combination of capivasertib, abiraterone, and ADT versus the standard combination of abiraterone and ADT in patients with newly diagnosed metastatic hormone-sensitive prostate cancer. The biomarker-driven approach specifically enrolled patients with PTEN-deficient tumors, identified through tissue testing.

The overwhelming 7-1 committee vote suggests the clinical data demonstrated meaningful improvement in patient outcomes while maintaining an acceptable safety profile. Advisory committee members typically scrutinize both efficacy benefits and potential risks, making such a decisive vote particularly significant.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Market Impact and Competitive Landscape

If approved, TRUQAP would become the first AKT inhibitor approved for prostate cancer treatment, potentially establishing AstraZeneca as a leader in precision oncology for this indication. The metastatic hormone-sensitive prostate cancer market is highly competitive, with established treatments including abiraterone (Zytiga), apalutamide (Erleada), and darolutamide (Nubeqa).

The biomarker-driven approach could differentiate TRUQAP in the crowded mHSPC landscape, though the PTEN-deficient population represents a subset of the broader patient population. This precision medicine strategy aligns with growing trends toward personalized cancer treatment based on tumor genetics.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for oncology - prostate cancer pricing, access, and launch sequencing.

Regulatory Timeline and Next Steps

The FDA is expected to make its final approval decision by August 2025. While advisory committee recommendations are not binding, the FDA typically follows committee guidance, particularly when the vote margin is substantial. The strong 7-1 vote suggests high confidence in the drug’s benefit-risk profile.

For AstraZeneca, TRUQAP approval would strengthen the company’s oncology portfolio and validate its precision medicine strategy. The company has been investing heavily in biomarker-driven cancer treatments, and capivasertib represents a key asset in this approach.

IntelligenceStrategic Takeaways▾

FDA Advisory Committee voted 7-1 in favor of TRUQAP (capivasertib) for PTEN-deficient metastatic hormone-sensitive prostate cancer The recommendation is based on positive results from the CAPItello-281 Phase III trial showing favorable benefit-risk profile FDA decision expected by August 2025, potentially bringing first AKT inhibitor to prostate cancer treatment

Implications for Patient Care

If approved, TRUQAP would provide a new treatment option for patients whose tumors lack functional PTEN protein. These patients often have more aggressive disease and may not respond as well to standard hormone therapies. The combination approach could potentially improve outcomes for this challenging patient population.

Healthcare providers would need to incorporate PTEN testing into routine practice to identify appropriate candidates for TRUQAP treatment. This requirement for companion diagnostics reflects the broader shift toward precision oncology in prostate cancer care.

---

Frequently Asked Questions

What does this FDA Advisory Committee recommendation mean for patients?

The 7-1 favorable vote significantly increases the likelihood of FDA approval for TRUQAP, potentially providing a new treatment option for patients with PTEN-deficient metastatic prostate cancer by August 2025. Patients would need genetic testing to determine if their tumors are PTEN-deficient and eligible for this targeted therapy.

When will TRUQAP be available if approved?

The FDA is expected to make its final approval decision by August 2025. If approved, TRUQAP would likely become available shortly after, though patients would need PTEN testing to determine eligibility for this biomarker-driven treatment.

How does TRUQAP compare to existing prostate cancer treatments?

TRUQAP would be the first AKT inhibitor approved for prostate cancer, offering a precision medicine approach for PTEN-deficient tumors. Unlike current standard treatments, it specifically targets patients based on genetic biomarkers, potentially providing better outcomes for this subset of patients who often have more aggressive disease.

IntelligenceEvidence Quality▾

Claims are grounded in the cited primary and secondary sources, with editorial review applied before publication.

Related profiles

• TRUQAP
• abiraterone

Related coverage

• AstraZeneca and Daiichi Sankyo datopotamab deruxtecan hits lung cancer endpoint
• Breast Cancer Statistics Worldwide: What the Data Shows
• BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial